Roth Capital Brokers Decrease Earnings Estimates for APVO

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Research analysts at Roth Capital decreased their Q1 2025 earnings estimates for shares of Aptevo Therapeutics in a research report issued on Monday, February 17th. Roth Capital analyst J. Aschoff now anticipates that the biotechnology company will post earnings of ($4.21) per share for the quarter, down from their previous forecast of ($3.92). The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($14.81) per share. Roth Capital also issued estimates for Aptevo Therapeutics’ Q2 2025 earnings at ($4.16) EPS, Q3 2025 earnings at ($3.78) EPS, Q4 2025 earnings at ($3.74) EPS, FY2025 earnings at ($15.84) EPS, FY2026 earnings at ($14.49) EPS, FY2027 earnings at ($10.03) EPS and FY2028 earnings at ($3.57) EPS.

Separately, StockNews.com started coverage on shares of Aptevo Therapeutics in a research note on Monday, December 9th. They set a “sell” rating on the stock.

Aptevo Therapeutics Price Performance

Shares of NASDAQ:APVO opened at $3.35 on Thursday. The company’s fifty day moving average is $4.36 and its two-hundred day moving average is $234.52. Aptevo Therapeutics has a 12-month low of $3.01 and a 12-month high of $399.60.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.